FIELD: biotechnology.
SUBSTANCE: disclosed is a liquid pharmaceutical composition containing an anti-PD-1/HER2 bispecific antibody, a buffer, a stabilizer and a surfactant. Also disclosed is a solid composition of the antibody in the form of a lyophilised powder, obtained by solidifying said liquid composition.
EFFECT: invention provides anti-PD-1/HER2 bispecific antibody protein stabilization during storage.
7 cl, 8 dwg, 20 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| MULTI-SPECIFIC ANTIBODIES AND METHODS OF THEIR PRODUCTION AND USE | 2018 |
|
RU2811477C2 |
| BISPECIFIC ANTIBODY | 2020 |
|
RU2814713C2 |
| HIGH-AFFINITY ANTI-PD-1 AND ANTI-LAG-3 ANTIBODIES AND BISPECIFIC BINDING PROTEINS OBTAINED FROM THEM | 2019 |
|
RU2782381C2 |
| TETRAVALENT SYMMETRICAL BISPECIFIC ANTIBODIES | 2019 |
|
RU2807346C2 |
| MOLECULES BINDING WITH CD38 AND PD-L1 | 2017 |
|
RU2764201C2 |
| ANTI-PD-L1 ANTIBODY AND ITS USE | 2020 |
|
RU2783685C2 |
| IMMUNE TOLERANCE INDUCING ANTIBODIES, INDUCED LYMPHOCYTES AND THERAPEUTIC AGENT/METHOD OF CELL THERAPY USING INDUCED LYMPHOCYTES | 2019 |
|
RU2816592C2 |
| PHARMACEUTICAL COMPOSITION OF THE FUSION PROTEIN OF THE TRANSFORMING GROWTH FACTOR BETA RECEPTOR AND ITS APPLICATION | 2019 |
|
RU2791683C2 |
| NEW ANTI-PD-L1 ANTIBODIES | 2017 |
|
RU2744959C2 |
| NEW ANTI-PD-L1 ANTIBODIES | 2017 |
|
RU2776121C2 |
